Analyse d'un complément en ltl dans la construction des verbes de mouvement Coréens

홍채성 연세대학교 인문학연구원 1983 人文科學 Vol.49 No.-

Treatment Effect of Combining Lenvatinib and Vemurafenib for BRAF Mutated Anaplastic Thyroid Cancer

홍채문,오지민,GANGADARAN PRAKASH,Ramya Lakshmi Rajendran,안병철 대한갑상선학회 2021 International Journal of Thyroidology Vol.14 No.2

Background and Objectives: Even though most of the thyroid cancer shows good prognosis, de-differentiatedthyroid cancer is still refractory to conventional treatments. Recently, kinase inhibitors including multi-kinase andBRAF inhibitors are widely used for treatment of de-differentiated thyroid cancers, but resistant to single kinaseinhibitor treatment eventually encountered. Therefore, combination therapy may have better therapeutic effectthan single therapy for thyroid cancer. In this study, we evaluated therapeutic effect of multi-kinase and BRAFinhibitor combination to anaplastic thyroid cancer cell lines with and without BRAF mutation. Materials andMethods: We used anaplastic thyroid cancer cell lines with BRAFV600E mutation (8505C) and with NRAS mutation(HTh7). Both cell lines were treated with various concentration of multi-kinase inhibitor (lenvatinib) and BRAFinhibitor (vemurafenib). And combination of various concentration of both kinase inhibitors were used to treatboth cell lines. Cytotoxic effect was assessed with cell counting kit-8 and therapeutic effect of single kinaseinhibitor therapy and the combination therapy was compared. Results: Anti-proliferative effect of vemurafenibon 8505C BRAFV600E-mutated cells was demonstrated from 0.25 μM concentration. However, HTh7 cells withNRAS mutation represented drug resistance up to 4 μM of vemurafenib. In case of lenvatinib treatment as amulti-kinase inhibitor, 8505C and HTh7 cells showed decreased cell viability dose-dependent manner. Combinationtreatment with vemurafenib and lenvatinib showed synergistic cytotoxic effect in BRAF mutated 8505C cell line,even at lower concentrations. Conclusion: Combination treatment with multi-kinase inhibitor and BRAF inhibitorshowed promising therapeutic results in BRAF mutated anaplastic thyroid cancer cell line.

KSNM60 in Nuclear Endocrinology: from the Beginning to the Future

홍채문,정영진,김해원,안병철 대한핵의학회 2022 핵의학 분자영상 Vol.56 No.1

Nuclear endocrinology is the main ignitor for founding the Korean Society of Nuclear Medicine (KSNM) in the early 1960s by outstanding pioneering medical doctors. Management of thyroid diseases required nuclear medicine technology in the early days of the KSNM and was rapidly developed by advancements in nuclear medicine technology. Nuclear thyroidology remains one of the main clinical applications in nuclear medicine worldwide. Nuclear medicine technology provides essential information for diagnosing and assessing diseases of the parathyroid glands, pituitary gland, and neuroendocrine tumors (NETs). In addition, therapeutic nuclear medicine is essential for managing nonresectable NETs. Nuclear endocrinology remains a major section in clinical nuclear medicine, and members of the KSNM have contributed to progressing better management of benign and malignant endocrine diseases. This review summarizes the historical activities and milestone contributions to nuclear endocrinology made by the members of the KSNM over the past 60 years to congratulate the KSNM on its 60-year anniversary.

Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer

홍채문,안병철 대한핵의학회 2018 핵의학 분자영상 Vol.52 No.4

Radioactive iodine (RAI) therapy for differentiated thyroid cancer has been successfully used for more than 70 years. However,there is still plenty of controversy surrounding the use and doses of radioiodine. There is insufficient evidence to answer thequestions. Recent American Thyroid Association (ATA) guidelines seem to favor low-dose RAI, based on recent clinical trialsand meta-analyses. However, long-term follow-up data remains limited, and there are additional factors we should consider thatmight affect the efficacy of RAI therapy. Therefore, until sufficient data are available, it is necessary to remain cautious aboutdetermining RAI doses by considering multiple patient-specific variables.

Clinical Characteristics of Pediatric Thalassemia in Korea:A Single Institute Experience

홍채리,강형진,이지원,김혜리,김남희,박경덕,박준동,성문우,박성섭,신희영,안효섭 대한의학회 2013 Journal of Korean medical science Vol.28 No.11

Few literatures have elaborated on the clinical characteristics of children with thalassemia from low-prevalence areas. A retrospective analysis was conducted on children genetically confirmed with thalassemia at Seoul National University Children’s Hospital in Korea. Nine children (1α thalassemia trait, 6β thalassemia minor, 2β thalassemia intermedia) were diagnosed with thalassemia at median age of 4.3 yr old with median hemoglobin of 9.7 g/dL. Seven (78%) children were incidentally found to be anemic and only 2 with β thalassemia intermedia had presenting symptoms. Five children (56%) were initially misdiagnosed with iron deficiency anemia. Despite the comorbidities due to α thalassemia mental retardation syndrome, the child with α thalassemia trait had mild hematologic profile. Children with β thalassemia intermedia had the worst phenotypes due to dominantly inherited mutations. None of the children was transfusion dependent and most of them had no complications associated with thalassemia. Only 1 child (11%) with codon 60 (T→A) mutation of the HBB gene needed red blood cell transfusions. He also had splenomegaly, cholelithiasis, and calvarial vault thickening. Pediatricians in Korea must acknowledge thalassemia as a possible diagnosis in children with microcytic hypochromic hemolytic anemia. High level of suspicion will allow timely diagnosis and managements.

YOLOv5를 이용한 건설현장 신호수 및 작업자 안전모니터링

홍채원 ( Hong Chae-won ),이승수 ( Lee Seung-soo ),문세범 ( Mun Se-bum ),한동엽 ( Han Dong-yeop ),박승희 ( Park Seung-hee ) 한국구조물진단유지관리공학회 2022 한국구조물진단유지관리공학회 학술발표대회 논문집 Vol.26 No.2

산업재해 사고사망 중 건설 기계·장비로 인한 사망사고가 많은 비중을 차지하고 있는 만큼 건설현장에서의 신호수 역할은 매우 중요하다. 하지만 실제 현장에서는 신호수의 부재로 인한 안전사고 또한 다수 발생하고 있어 신호수 배치가 제대로 이루어지지 않고 있음을 알 수 있다. 그러나 아직까지는 건설현장에서의 신호수 배치 관련 연구가 아직 활발히 이루어지지 않고 있는 실정이다. 따라서 본 연구에서는 YOLOv5를 이용하여 건설현장에 신호수가 배치되었는지 확인할 수 있는 안전 모니터링 기술을 개발하였다. 연구 결과, 일반작업자와 신호수 구분을 88.1%의 정확도로 분류하였다. 본 연구 결과는 신호수 부재로 인한 건설 중장비로 인한 안전사고를 예방하는데 기여할 수 있다.

YOLOv7을 이용한 건설현장 작업자 및 신호수 모니터링

홍채원(Hong, Chae Won),김한선(Kim, Han Sun),박승희(Park, Seung Hee) 한국콘크리트학회 2023 한국콘크리트학회 학술대회 논문집 Vol.35 No.2

Extra-cranial Malignant Rhabdoid Tumor in Children: A Single Institute Experience

홍채리,강형진,주희영,이지원,김혜리,박성혜,김일한,박경덕,신희영 대한암학회 2015 Cancer Research and Treatment Vol.47 No.4

Purpose Malignant rhabdoid tumor (MRT) is a rare and highly aggressive tumor that affects youngchildren. Due to its extreme rarity, most of the available data are based on retrospectivecase series. To add to the current knowledge of this disease, we reviewed the patientstreated for extra-cranial MRT in our institute. Materials and MethodsA retrospective medical record review was conducted on children treated for pathologicallyconfirmed extra-cranial MRT at Seoul National University Children’s Hospital betweenJanuary 2003 and May 2013. ResultsEleven patients (7 boys, 4 girls) were diagnosed with extra-cranial MRT at a median age of9 months old. INI1 staining was important in the pathological confirmation. Six patients(55%) had renal MRT and five (45%) had soft tissue MRT. Five patients (45%) had metastasesat diagnosis. All patients underwent chemotherapy, eight patients (73%) underwentsurgery, six patients (55%) received therapeutic radiotherapy, and four patients (36%)underwent high dose chemotherapy with autologous stem cell rescue (HDCT/ASCR) withmelphalan, etoposide, and carboplatin. Five patients (45%) died of disease followingprogression (n=3) or relapse (n=2), however, there was no treatment related mortality. Theoverall survival of the cohort was 53.0% and the event-free survival was 54.5% with amedian follow-up duration of 17.8 months (range, 2.3 to 112.3 months). ConclusionExtra-cranial MRT is still a highly aggressive tumor in young children. However, the improvedsurvival of our cohort is promising and HDCT/ASCR with melphalan, etoposide, and carboplatinmay be a promising treatment option.

Second Primary Malignancy After Radioiodine Therapy in Thyroid Cancer Patient: A Nationwide Study

홍채문 대한핵의학회 2023 핵의학 분자영상 Vol.57 No.6

Objective This study aimed to investigate the risk of second primary malignancy after radioiodine (RAI) therapy in patientswith thyroid cancer, using the National Health Insurance Service (NHIS) database. Methods We extracted data from the NHIS database of South Korea, which covers the entire population of the nation. Riskof second primary malignancy in the thyroid cancer patients who received RAI therapy were compared with the thyroidcancer patients who received surgery only. Results Between January 1, 2004, and December 31, 2018, we identified 363,155 patients who underwent thyroid surgerydue to thyroid cancer for analysis. The surgery only cohort was 215,481, and the RAI cohort was 147,674 patients. A totalof 19,385 patients developed second primary malignancy (solid cancer, 18,285; hematologic cancer, 1,100). There was nosignificant increase in the risk of second primary malignancy in patients who received a total cumulative dose of 100 mCi orless (hazard ratio [HR], 1.013; 95% confidence interval [CI], 0.979–1.049). However, a statistically significant increase in therisk of second primary malignancy was observed in patients who received 101–200 mCi (HR, 1.214; 95% CI, 1.167–1.264),201–300 mCi (HR, 1.422; 95% CI, 1.258–1.607), and > 300 mCi (HR, 1.693; 95% CI, 1.545–1.854). Conclusion Total cumulative doses of 100 mCi or less of RAI can be safely administered without concerns about secondprimary malignancy. However, the risk of second primary malignancy increases in a dose-dependent manner, and the risk–benefit needs to be considered for doses over 100 mCi of RAI therapy.

Carotid-Sparing TomoHelical 3-Dimensional Conformal Radiotherapy for Early Glottic Cancer

홍채선,오동렬,주상규,안용찬,노재명,정광주,김진성,서태석 대한암학회 2016 Cancer Research and Treatment Vol.48 No.1

Purpose The purpose of this study was to investigate the dosimetric benefits and treatment efficiency of carotid-sparing TomoHelical 3-dimensional conformal radiotherapy (TH-3DCRT) for early glottic cancer. Materials and Methods Ten early-stage (T1N0M0) glottic squamous cell carcinoma patients were simulated, based on computed tomography scans. Two-field 3DCRT (2F-3DCRT), 3-field intensity-modulated radiation therapy (3F-IMRT), TomoHelical-IMRT (TH-IMRT), and TH-3DCRT plans were generated with a 67.5-Gy total prescription dose to the planning target volume (PTV) for each patient. In order to evaluate the plan quality, dosimetric characteristics were compared in terms of conformity index (CI) and homogeneity index (HI) for PTV, dose to the carotid arteries, and maximum dose to the spinal cord. Treatment planning and delivery times were compared to evaluate treatment efficiency. Results The median CI was substantially better for the 3F-IMRT (0.65), TH-IMRT (0.64), and TH-3DCRT (0.63) plans, compared to the 2F-3DCRT plan (0.32). PTV HI was slightly better for TH-3DCRT and TH-IMRT (1.05) compared to 2F-3DCRT (1.06) and 3F-IMRT (1.09). TH-3DCRT, 3F-IMRT, and TH-IMRT showed an excellent carotid sparing capability compared to 2F-3DCRT (p < 0.05). For all plans, the maximum dose to the spinal cord was < 45 Gy. The median treatment planning times for 2F-3DCRT (5.85 minutes) and TH-3DCRT (7.10 minutes) were much lower than those for 3F-IMRT (45.48 minutes) and TH-IMRT (35.30 minutes). The delivery times for 2F-3DCRT (2.06 minutes) and 3F-IMRT (2.48 minutes) were slightly lower than those for TH-IMRT (2.90 minutes) and TH-3DCRT (2.86 minutes). Conclusion TH-3DCRT showed excellent carotid-sparing capability, while offering high efficiency and maintaining good PTV coverage.